From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain
Por:
Crépey P, Redondo E, Díez-Domingo J, Ortiz de Lejarazu R, Martinón-Torres F, Gil de Miguel Á, López-Belmonte JL, Alvarez FP, Bricout H and Solozabal M
Publicada:
21 may 2020
Ahead of Print:
21 may 2020
Categoría:
Multidisciplinary
Resumen:
Purpose
Quadrivalent influenza vaccine (QIV) includes the same strains as trivalent influenza vaccine (TIV) plus an additional B strain of the other B lineage. The aim of the study was to analyse the public health and economic impact of replacing TIV with QIV in different scenarios in Spain.
Methods
A dynamic transmission model was developed to estimate the number of influenza B cases prevented under TIV and QIV strategies (< 65 years (high risk) and >= 65 years). This model considers cross-protective immunity induced by different lineages of influenza B. The output of the transmission model was used as input for a decision tree model that estimated the economic impact of switching TIV to QIV. The models were populated with Spanish data whenever possible. Deterministic univariate and probabilistic multivariate sensitivity analyses were performed.
Results
Replacing TIV with QIV in all eligible patients with current vaccine coverage in Spain may have prevented 138,707 influenza B cases per season and, therefore avoided 10,748 outpatient visits, 3,179 hospitalizations and 192 deaths. The replacement could save (sic) 532,768 in outpatient visit costs, (sic) 13 million in hospitalization costs, and (sic) 3 million in costs of influenza-related deaths per year. An additional (sic) 5 million costs associated with productivity loss could be saved per year, from the societal perspective. The budget impact from societal perspective would be (sic) 6.5 million, and the incremental cost-effectiveness ratio (ICER) (sic) 1,527 per quality-adjusted life year (QALY). Sensitivity analyses showed robust results. In additional scenarios, QIV also showed an impact at public health level reducing influenza B related cases, outpatient visits, hospitalizations and deaths.
Conclusions
Our results show public health and economic benefits for influenza prevention with QIV. It would be an efficient intervention for the Spanish National Health Service with major health benefits especially in the population.65-year.
Filiaciones:
Crépey P:
Department of Quantitative Methods in Public Health, UPRES-EA-7449 Reperes, EHESP, University of Rennes, Rennes, France
Redondo E:
Centro de Salud Internacional Madrid Salud, Ayuntamiento de Madrid, Madrid, Spain
:
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Valencia, Spain
Ortiz de Lejarazu R:
Centro Nacional de Gripe de Valladolid, Hospital Clínico Universitario de Valladolid, Valladolid, Spain
Martinón-Torres F:
Servicio Pediatría, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain
Grupo de Genética, Infecciones y Vacunas en Pediatría (GENVIP), Instituto de Investigación Sanitaria de Santiago, Universidad de Santiago de Compostela, Santiago de Compostela, Spain
Gil de Miguel Á:
Departamento de Medicina Preventiva y Salud Pública, Universidad Rey Juan Carlos, Madrid, Spain
López-Belmonte JL:
Sanofi Pasteur España, Madrid, Spain
Alvarez FP:
Sanofi Pasteur Global, Lyon, France
Bricout H:
Sanofi Pasteur Europe, Lyon, France
Solozabal M:
IQVIA, Madrid, Spain
Green Published, gold
|